Archive →
Daily Morning Briefing

Sunday, 10 May 2026

Day two of the Russia–Ukraine 9–11 May ceasefire · pared-down Victory Day done · Magyar sworn in as Hungary's PM · Trump–Xi Beijing summit Thursday–Friday · US April CPI Tuesday
Europe/Rome 06:00 · Markets closed · S&P/Nasdaq at records · CPI & Trump–Xi this week

Top of the morning

Markets snapshot — Friday 8 May close (weekend levels)

Cash markets are closed for the weekend; figures below are Friday's close or the latest available print. Asia futures resume Sunday evening Rome time; European cash open Monday at 09:00 CET.

InstrumentLastChange / context
S&P 5007,399+0.8% Fri · +2.3% wk · record close
Nasdaq Composite26,247+1.7% Fri · +4.5% wk · record close
Dow Jones49,609~flat Fri · ~+0.2% wk
STOXX 600~623modest weekly gain · capped late by EU tariff threat
FTSE 100−1.26% wk · politics-driven
DAX~24,920+0.19% wk
FTSE MIB+2.16% wk · best in Europe
Nikkei 225 (Fri)Asia broadly lower on Iran/Hormuz nerves
Hang Seng (Fri)−0.85% Fri
CSI 300 (Fri)~4,872−0.58% Fri
US 10y Treasury4.38%~−3bp Fri · two-week low
UK 30y gilt~5.54–5.58%eased on Starmer's vow to stay
EUR/USD1.1748+0.19% Fri · 3-week high · hawkish ECB pricing
GBP/USD~1.36firmer · vs EUR ~0.864
Brent crude~$101−6%+ wk · Hormuz tanker exchange Friday
WTI crude~$95−6%+ wk · choppy on Hormuz flow
Gold (XAU)~$4,720+>2% wk · highest since 22 Apr

Geopolitics & weekend watch

Two stories dominate the geopolitical tape into Asia's Sunday-evening open. First, the Russia–Ukraine ceasefire window. Day one delivered the Victory Day optics — a stripped-down Red Square parade with Xi alongside Putin and no military hardware on display, the first time in nearly two decades — but on the line both sides logged hundreds of breaches, Ukraine struck a Russian oil facility in Yaroslavl, and the Kremlin claimed to have downed a large number of Ukrainian drones. The structural read is unchanged: Ukraine is planning around a long-arc war, Russia is using the parade week to project status and lock in optionality, and the ceasefire window is theatre rather than a settlement. The hard signal to watch tonight is the actual drone tempo against the framework — and any change in Russian framing of conditions for an extension. Witkoff–Yermak channel chatter has not produced a public read-out yet.

Second, the Iran-Hormuz track. The diplomatic line is still moving via Pakistan toward a one-page MOU on enrichment moratorium, asset unfreeze and Hormuz security, while CENTCOM has announced an open passage through the Strait for the first time since the blockade was tightened. The skirmish residue has not gone away — Friday's tanker exchanges and the Iranian missile launch at the UAE are the operational counter-evidence — which is why gold is bid and oil is no longer falling in a straight line. Bloomberg's read this morning is that Trump's plan now waits on Tehran's answer; expect that timing to be the binding signal for the energy complex into next week. Adnoc's earlier-week practice of switching off AIS transponders to push Gulf LNG through Hormuz is the more durable signal than any single press release, and Italian energy and EU LNG security planners should treat it as such.

Three smaller threads worth tracking. Magyar's swearing-in in Budapest is a meaningful regime change for CEE risk premia and the Article 7 file. One Nation's first House seat in Australia is a populist data-point in the same arc as Reform UK and Le Pen. China is using the week before Trump–Xi to remind Washington that "compliance" runs both ways — blocking new bank loans to a US-sanctioned refiner, the implicit Nvidia/Alibaba/Thailand trail, and Beijing's call on Germany and France to push back against EU "protectionist drift."

Central banks & the rate-cut narrative

The April Employment Situation has done the heaviest lifting of the week into the Fed's CPI date. The combination of better-than-feared payrolls, sticky 4.3% unemployment and a clear cooling in average hourly earnings is the cleanest "low-hire, low-fire, lower-pressure" print the Fed could have hoped for. Money is still pricing the Fed sitting at 3.50–3.75% into 2027, but the dispersion has widened. Goldman has pushed its first-cut call to December, then March; a downside CPI surprise on Tuesday opens the September meeting back up, while a strong print pushes the next cut into early 2027. Goolsbee has explicitly said all options are on the table, Waller on Friday flagged that regional Feds will centralise some functions, and Boston's Collins gave a measured FOMC-dissent read. The sequencing matters because equity leadership is leaning so heavily on the AI-capex / mega-cap tech complex that any meaningful repricing of the front-end will hurt valuation more than earnings. Layered on top: the Senate is expected to vote on Kevin Warsh's nomination to succeed Powell as Fed chair this week — Powell's term ends Friday 15 May.

In Europe the picture is mirrored. Hawkish ECB voices (Nagel calling the council "highly vigilant" to rising inflation risks, Kazimir, Escrivá flagging AI-driven financial-infrastructure review) have been validated by EUR strength and money-market repricing; the council split over a June hike is now a meaningful probability rather than a tail. Lagarde's "torn between too early and too late" line on Friday is the most candid read of the dilemma. The BoE post-decision tone is what GBP at ~1.36 is digesting; politics from the local elections is the local risk to gilts but, with Starmer staying for now, the immediate fiscal-loosening tail has been priced down. Hungary continues to flag a possible June rate move on a strong forint, now politically clearer post-Magyar. For physician–investor types, the practical takeaway is unchanged: long-duration healthcare equities and biotech remain a leveraged play on the rate path, and Tuesday's CPI is the next inflection.

Big Tech, AI & corporates

The China-tech decoupling story moved from background to foreground this week. The Bloomberg-broken Nvidia/Alibaba/Thailand chain (Bangkok-based OBON Corp routing about $2.5bn of Super Micro servers to Chinese end-customers in 2024–25) is not a one-off anecdote; it implies the export-control architecture is leaking through intermediaries that Washington only intermittently sees. China responded operationally — pausing new loans to a US-sanctioned refiner, blocking Meta's Manus AI deal, quietly tightening on outbound capital — and ByteDance is reportedly raising AI-infrastructure capex by 25%. Apple's late-stage AirPods-with-camera testing and the new-CEO framing in Bloomberg's Power On column are the consumer-side illustration of the same pressure: control the device, control the input layer, reduce dependence on partners. For the index, this remains a tape that rewards mega-cap tech while the underlying structural risk increases — a tension the equity market has been quite content to ignore as long as earnings deliver.

Around the edges. Apollo and Blackstone weighing a $35bn Broadcom financing keeps the private-credit-vs-banks tussle (banks now winning more business as private debt shrinks) front of mind. Vodafone's $5.8bn UK telco buyout consolidates UK mobile. Datadog's largest one-day move in six years on a guidance raise capped a strong tech-earnings week. Honeywell-backed Quantinuum filed for a US IPO — the first quantum-computing pure-play of size on the path. Saudi delivery app Ninja tapped banks for a $1bn IPO. Wall Street bonus pools are now guided up, with M&A bankers tagged for a 20%+ pop. The Pulitzer Prizes 2026 went to Bloomberg News for the trAPPed graphic investigation into India's wave of digital arrests — niche but worth flagging for EM-fintech and India-digitalisation read-throughs.

Health & science (worth a glance)

The physician-shortage thread that started as a political story is now structural. Even with selective walk-backs, the AY 2026–27 residency and fellowship pipelines for the 1 July start are functionally locked — meaning the service-line impact is already determined for this autumn. DOJ's UCLA medical school case opens a fresh DEI-in-medical-education front whose downstream effects on the match and on residency-program funding are not yet priced in. Adjacent: the cruise-ship hantavirus cluster — high case fatality (~30–40% in severe HPS) but very low person-to-person transmissibility — is the kind of outbreak whose pandemic-tail framing was overstated all week; the more durable angle, as Bloomberg Businessweek frames it, is travel and reinsurance exposure to cross-border detection gaps.

On the AI-in-clinical-workflows track, ambient documentation tooling is the most consequential near-term lever for clinician throughput; the AirPods camera concept is upstream of the same direction of travel. GLP-1 demand metrics remain firm into the second half despite ongoing supply normalization; Novo Nordisk's Ozempic India price cut is materially boosting volumes — a useful EM-pharma volume-vs-price datapoint. The Businessweek thread on midlife-male preventive cardio / TRT demand is a demand-side marker rather than a clinical signal. Watch for follow-ups on antibiotic stewardship and new RSV antiviral data into the AHA / IDSA cycles later this year.

Week ahead (CET)